Expert Opinion on Pharmacotherapy

How much is patent protection threatened by drug costs?
pp. 1863-1865(3)
Author: Bebe Loff

Evaluation and review of pharmacoeconomic models
pp. 1867-1880(14)
Author: Joel W Hay

Cost-effectiveness of TNF--blocking agents in the treatment of rheumatoid arthritis
pp. 1881-1886(6)
Authors: Sonja Merkesdal; Jörg Ruof; Thomas Mittendorf; Henning Zeidler

Pharmacoeconomics of low-molecular-weight heparins: limitations of studies comparing them to unfractionated heparin
pp. 1887-1897(11)
Authors: Terry E Jones; Brian J Smith; Jonathen F Polasek

Infective endocarditis: a review of the best treatment options
pp. 1899-1916(18)
Authors: Leonardo Calza; Roberto Manfredi; Francesco Chiodo

Recent pharmacological advances in the treatment of preterm membrane rupture, labour and delivery
pp. 1917-1928(12)
Author: Sheila A Doggrell

The treatment of neoplastic meningitis
pp. 1929-1935(7)
Authors: Terri S Armstrong; Mark R Gilbert

Current treatment practices in the management of cutaneous haemangioma
pp. 1937-1942(6)
Author: Yuin-Chew Chan

An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence
pp. 1943-1955(13)
Author: Bankole A Johnson

After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia
pp. 1957-1964(8)
Author: Sheila A Doggrell

A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases
pp. 1965-1977(13)
Authors: Claudio Borghi; Stefano Bacchelli; Daniela Degli Esposti; Ettore Ambrosioni

A review of olopatadine for the treatment of ocular allergy
pp. 1979-1994(16)
Author: Mark B Abelson

Fosamprenavir: advancing HIV protease inhibitor treatment options
pp. 1995-2005(11)
Authors: Stephen Becker; Lorna Thornton

Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host
pp. 2007-2016(10)
Author: Richard B Freeman

Botulinum toxin A for the treatment of cervical dystonia
pp. 2017-2024(8)
Authors: Theresa A Zesiewicz; William Stamey; Kelly L Sullivan; Robert A Hauser

Atorvastatin versus pravastatin: intensive versus moderate lipid lowering
pp. 2025-2028(4)
Author: Sheila A Doggrell

Corrigendum
pp. 2051-2051(1)